{"nctId":"NCT01462318","briefTitle":"An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis","startDateStruct":{"date":"2011-11"},"conditions":["Relapsing-Remitting Multiple Sclerosis"],"count":133,"armGroups":[{"label":"DAC HYP","type":"EXPERIMENTAL","interventionNames":["Drug: Midazolam","Other: Caffeine","Drug: S-warfarin","Other: Vitamin K","Drug: Omeprazole","Drug: Dextromethorphan","Biological: BIIB019 (Daclizumab)"]}],"interventions":[{"name":"Midazolam","otherNames":[]},{"name":"Caffeine","otherNames":[]},{"name":"S-warfarin","otherNames":[]},{"name":"Vitamin K","otherNames":[]},{"name":"Omeprazole","otherNames":[]},{"name":"Dextromethorphan","otherNames":[]},{"name":"BIIB019 (Daclizumab)","otherNames":["Daclizumab High Yield Process; DAC HYP"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Must have a confirmed diagnosis of RRMS according to McDonald criteria and previous cranial magnetic resonance imaging demonstrating lesion(s) consistent with MS\n* Must have a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive\n* Must have had 1 or more clinical relapses within the previous 2 years\n* Women of child bearing potential must be willing to practice effective contraception during the study and 4 months after the last dose\n\nKey Exclusion Criteria:\n\n* Other chronic disease of the immune system, malignancies, acute urologic, pulmonary, gastrointestinal disease\n* Female subjects who are currently pregnant or breastfeeding\n\nKey Inclusion criteria for 3-Year Treatment Extension:\n\nTo be eligible for participation in the 3-year treatment extension, participants must meet the following eligibility criteria at the time of reinitiation of DAC HYP:\n\n* Must have been compliant with the 205MS302 (NCT01462318) protocol during the initial 24-week treatment period and the 20-week washout period in the opinion of the Investigator\n* Must resume DAC HYP treatment ≤12 weeks after completion of the washout period (i.e., ≤12 weeks after their Week 44 visit).\n* Participants who are currently receiving an approved IFN ß preparation must discontinue interferon (IFN) ß treatment at the time of reinitiation of DAC HYP dosing (no washout is required).\n\nKey Inclusion criteria for the TP-DI Sub-study:\n\nTo be eligible for participation in the TP-DI Sub-Study, subjects must meet the following eligibility criteria at the Screening Visit at Week 40:\n\n* Must have been compliant with the 205MS302 (NCT01462318) protocol during the initial 24-week treatment period and through Week 40 of the 20-week washout period in the opinion of the Investigator.\n* Must agree to resume DAC HYP treatment ≤12 weeks after completion of the washout period (i.e., ≤12 weeks after their Week 44 visit).\n* Must have normal liver function test results (total bilirubin ≤1.5 × upper limit of normal (ULN), alanine aminotransferase/aspartate aminotransferase ≤2 × ULN, and prothrombin time/partial thromboplastin time ≤1.2 × ULN).\n* Must have normal renal function as estimated creatinine clearance \\>60 mL/min (Cockcroft-Gault formula).\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Anti-DAC HYP Binding Antibodies (ADAbs): Electrochemiluminescent (ECL) Anti-Drug Antibody (ADA) Assay","description":"Participants with post-baseline (PB) ADAbs through Week 44, in the treatment period (extends up to 42 days after the last dose during the main study), and in the post-treatment period (43 days after the last dose until the end of the post-treatment period dose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Anti-DAC HYP Neutralizing Antibodies (NAbs): ECL ADA Assay","description":"Participants with PB NAbs through Week 44, in the treatment period (extends up to 42 days after the last dose during the main study), and in the post-treatment period (43 days after the last dose until the end of the post-treatment period dose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"TP-DI Sub-study: Area-Under-the-Curve From Zero to Infinity (AUCinf) of Each Probe Drug","description":"AUCinf of each of the following cytochrome P450 (CYP) isoenzyme substrates: midazolam (CYP3A), S-warfarin + vitamin K (CYP2C9), and omeprazole (CYP2C19). The AUC from zero to 12 hours (AUC0-12) was calculated for caffeine (CYP1A2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"786.75","spread":"328.794"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"816.87","spread":"403.958"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19292.9","spread":"5524.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19609.3","spread":"4620.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2214.5","spread":"2622.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1770.0","spread":"1673.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35742.4","spread":"13942.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37449.2","spread":"14367.04"}]}]}]},{"type":"PRIMARY","title":"TP-DI Sub-study: Dextromethorphan to Dextrorphan Urine Concentration Ratio","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.42468","spread":"1.258565"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48939","spread":"1.813077"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Cmax of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.63","spread":"4.639"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.07","spread":"10.812"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Time to Reach Maximum Concentration (Tmax) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.31","spread":"6.368"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.41","spread":"3.273"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Area-Under-the-Curve From Start to End of the Dosing Interval (AUCtau) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"255.25","spread":"88.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"638.10","spread":"256.076"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Minimum Concentrations (Cmin) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.93","spread":"6.327"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Apparent Volume of Distribution (V/F) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.21","spread":"2.810"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Elimination Half-life (t½) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.92","spread":"5.473"}]}]}]},{"type":"SECONDARY","title":"Intensive PK Sub-study: Apparent Clearance (CL/F) of DAC HYP","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.108"}]}]}]},{"type":"SECONDARY","title":"TP-DI Sub-study: Cmax of Each Probe Drug","description":"Cmax of each of the following CYP isoenzyme substrates: midazolam (CYP3A), caffeine (CYP1A2), warfarin + vitamin K (CYP2C9), and omeprazole (CYP2C19).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"271.05","spread":"106.925"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"311.21","spread":"147.912"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4965.0","spread":"1312.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5399.5","spread":"1364.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"635.65","spread":"140.291"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"649.74","spread":"155.977"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"776.95","spread":"513.344"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"771.16","spread":"540.331"}]}]}]},{"type":"SECONDARY","title":"TP-DI Sub-study: CL/F of Each Probe Drug","description":"CL/F of each of the following CYP isoenzyme substrates: midazolam (CYP3A), warfarin + vitamin K (CYP2C9), and omeprazole (CYP2C19).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7625.7","spread":"3849.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7298.6","spread":"2844.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"565.86","spread":"184.129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"541.46","spread":"150.298"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41612.4","spread":"30003.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41772.4","spread":"29810.30"}]}]}]},{"type":"SECONDARY","title":"TP-DI Sub-study: Omeprazole/Hydroxyomeprazole Concentration Ratio at 2 Hours Post-omeprazole Dosing","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.673","spread":"4.7878"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.028","spread":"0.9297"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":33,"n":133},"commonTop":["Multiple sclerosis relapse","Upper respiratory tract infection","Urinary tract infection","Headache","Nasopharyngitis"]}}}